Analysts’ Ratings Reiterations for November 13th (ALFA, ALT, AMAT, AME, ARWR, ASND, CAPR, CRMD, CSCO, DERM)

Analysts’ ratings reiterations for Friday, November 13th:

Alfa Financial Software (LON:ALFA) had its buy rating reaffirmed by analysts at Berenberg Bank. Berenberg Bank currently has a GBX 260 target price on the stock.

Altimmune (NASDAQ:ALT) had its buy rating reaffirmed by analysts at B. Riley Financial.

Applied Materials (NASDAQ:AMAT) had its outperform rating reaffirmed by analysts at Royal Bank Of Canada. Royal Bank Of Canada currently has a $600.00 target price on the stock.

AMETEK (NYSE:AME) had its buy rating reiterated by analysts at Truist Financial. They currently have a $329.00 price target on the stock, up from their previous price target of $316.00.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its outperform rating reissued by analysts at Royal Bank Of Canada. The firm currently has a $100.00 target price on the stock.

Ascendis Pharma A/S (NASDAQ:ASND) had its outperform rating reaffirmed by analysts at Royal Bank Of Canada. The firm currently has a $290.00 target price on the stock.

Capricor Therapeutics (NASDAQ:CAPR) had its neutral rating reiterated by analysts at Roth Capital. Roth Capital currently has a $10.50 price target on the stock, up from their previous price target of $7.00.

CorMedix (NASDAQ:CRMD) had its outperform rating reiterated by analysts at Oppenheimer. They currently have a $13.00 price target on the stock, down from their previous price target of $15.00.

Cisco Systems (NASDAQ:CSCO) had its neutral rating reaffirmed by analysts at Piper Sandler. The firm currently has a $112.00 price target on the stock, down from their previous price target of $125.00.

Journey Medical (NASDAQ:DERM) had its buy rating reiterated by analysts at B. Riley Financial. They currently have a $13.00 price target on the stock, down from their previous price target of $15.00.

EZCORP (NASDAQ:EZPW) had its buy rating reiterated by analysts at Roth Capital. They currently have a $40.00 target price on the stock.

Presidio Production (NYSE:FTW) had its buy rating reaffirmed by analysts at BTIG Research. The firm currently has a $15.00 price target on the stock.

Global-e Online (NASDAQ:GLBE) had its overweight rating reiterated by analysts at Piper Sandler. They currently have a $52.00 price target on the stock.

ITG (NASDAQ:ITG) had its buy rating reaffirmed by analysts at Truist Financial. The firm currently has a $11.00 price target on the stock, down from their previous price target of $14.00.

Laird Superfood (NYSEAMERICAN:LSF) had its buy rating reiterated by analysts at Roth Capital. They currently have a $4.50 target price on the stock, down from their previous target price of $6.00.

Nebius Group (NASDAQ:NBIS) had its buy rating reaffirmed by analysts at Truist Financial. The firm currently has a $245.00 target price on the stock, down from their previous target price of $355.00.

Nebius Group (NASDAQ:NBIS) had its buy rating reissued by analysts at Rosenblatt Securities. Rosenblatt Securities currently has a $304.00 target price on the stock.

NU (NYSE:NU) had its buy rating reiterated by analysts at Needham & Company LLC. The firm currently has a $19.00 target price on the stock.

Everpure (NYSE:P) had its buy rating reissued by analysts at Guggenheim. Guggenheim currently has a $215.00 target price on the stock.

Tecogen (NYSEAMERICAN:TGEN) had its buy rating reiterated by analysts at Roth Capital. The firm currently has a $10.00 price target on the stock.

Tesla (NASDAQ:TSLA) had its sell rating reissued by analysts at Glj Research.

Vox Royalty (NASDAQ:VOXR) had its buy rating reaffirmed by analysts at Roth Capital. The firm currently has a $8.25 target price on the stock, down from their previous target price of $8.50.

VirTra (NASDAQ:VTSI) had its buy rating reiterated by analysts at Roth Capital. Roth Capital currently has a $7.50 price target on the stock.

YETI (NYSE:YETI) had its buy rating reiterated by analysts at Roth Capital. They currently have a $52.00 price target on the stock, down from their previous price target of $62.00.